0001209191-17-005210.txt : 20170123 0001209191-17-005210.hdr.sgml : 20170123 20170123191030 ACCESSION NUMBER: 0001209191-17-005210 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170120 FILED AS OF DATE: 20170123 DATE AS OF CHANGE: 20170123 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Flexion Therapeutics Inc CENTRAL INDEX KEY: 0001419600 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10 MALL ROAD STREET 2: SUITE 301 CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: (781) 305-7777 MAIL ADDRESS: STREET 1: 10 MALL ROAD STREET 2: SUITE 301 CITY: BURLINGTON STATE: MA ZIP: 01803 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bodick Neil CENTRAL INDEX KEY: 0001598099 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36287 FILM NUMBER: 17542264 MAIL ADDRESS: STREET 1: C/O FLEXION THERAPEUTICS, INC. STREET 2: 10 MALL ROAD, SUITE 301 CITY: BURLINGTON STATE: MA ZIP: 01803 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-01-20 0 0001419600 Flexion Therapeutics Inc FLXN 0001598099 Bodick Neil C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, SUITE 301 BURLINGTON MA 01803 0 1 0 0 Chief Medical Officer Common Stock 2017-01-20 4 S 0 5000 18.3494 D 60937 D Common Stock 388683 I By Versant Development Fund III, LLC Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted December 17, 2014. The weighted average sale price for the transaction reported was $18.3494, and the range of prices were between $18.16 and $18.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares. /s/ Frederick Driscoll, Attorney-in-Fact 2017-01-23